One blood test can rise or fall for reasons that have nothing to do with cancer, and millions of men taking a common prostate drug may be reading their results wrong.
Quick Take
- The PSA blood test checks a protein made by the prostate, but federal health guidance says it is not specific to cancer.
- Doctors do not recommend routine PSA screening for all men; it depends on individual risk factors.
- The drug finasteride, used for hair loss and enlarged prostate, can cut PSA levels roughly in half.
- Benign conditions like infections or an enlarged prostate can also push PSA numbers up without cancer being present.
- Experts say tracking PSA changes over time matters more than any single number.
What the PSA Test Actually Measures
The prostate-specific antigen (PSA) test checks for a protein made by prostate cells. Doctors have used it for decades to help spot possible prostate cancer. But the National Cancer Institute says the test is not recommended as routine screening for every man. Instead, it says higher-risk men should talk with their doctor about whether testing makes sense for them.
That distinction matters because PSA is prostate-specific, not cancer-specific. The protein shows up when something is happening in the prostate, but it cannot tell doctors what that something is. A high number does not automatically mean cancer, and a normal number does not rule it out.
Common Conditions That Raise or Lower the Number
Several ordinary, non-cancerous conditions can push PSA levels higher. Clinical research backed by the National Cancer Institute lists an enlarged prostate, prostate infections, urinary retention, recent ejaculation, and even medical procedures as causes of elevated readings. This means a single high result often leads to further testing rather than an immediate cancer diagnosis, since many men with raised PSA levels turn out not to have cancer at all.
On the flip side, some medications lower PSA and can mask a problem if doctors do not account for it. Finasteride, sold under brand names for hair loss and prescribed more broadly for an enlarged prostate, is the clearest example. The Food and Drug Administration’s (FDA) official label states plainly that finasteride causes a decrease in blood PSA levels, and it instructs patients to tell their doctor if they are taking the drug before getting tested.
Why a Single Test Can Mislead
Federal drug labeling goes further, explaining that doctors should watch for any confirmed rise from a patient’s lowest PSA level while on finasteride. That rise can signal a problem worth checking, even if the number still falls within what looks like a normal range. This means doctors are told to track trends over time, not just compare one test to a generic cutoff shared by every patient.
Research on the Prostate Cancer Prevention Trial adds more context. Scientists found finasteride reduced the overall number of prostate cancer cases detected, but the findings also raised questions about higher-grade disease that required more analysis to sort out. A National Cancer Institute researcher involved in reviewing that trial noted the results needed careful follow-up study to fully explain the pattern.
Why Doctors Stress Trends Over Thresholds
Because so many factors can swing PSA levels up or down, doctors increasingly favor monitoring changes over time rather than treating any single cutoff as a hard line. A man’s own history becomes the baseline, and sudden or sustained shifts from that baseline carry more weight than comparing his number to a general population average.
For patients, the practical takeaway is straightforward. Anyone taking finasteride or a related drug should tell every doctor who orders a PSA test, since skipping that detail can throw off the entire interpretation. Anyone with questions about screening, especially men with family history or other risk factors, should raise the topic directly with their doctor rather than relying on a single number to settle the question.
Sources:
wellness.com, cancer.gov, accessdata.fda.gov, pmc.ncbi.nlm.nih.gov
